Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population

2020; Nature Portfolio; Volume: 10; Issue: 1 Linguagem: Inglês

10.1038/s41598-020-67312-y

2045-2322

Darlen Cardoso de Carvalho, Alayde Vieira Wanderley, André Maurício Ribeiro dos Santos, Fabiano Cordeiro Moreira, Roberta Borges Andrade de Sá, Marianne Rodrigues Fernandes, Antônio André Conde Modesto, Tatiane Piedade de Souza, Amanda de Nazaré Cohen-Paes, Luciana Pereira Colares Leitão, Juliana Carla Gomes Rodrigues, Artur Silva, João Farias Guerreiro, Sidney Emanuel Batista dos Santos, André Salim Khayat, Paulo Pimentel de Assumpção, Ney Pereira Carneiro dos Santos,

DNA Repair Mechanisms

Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children. Differences are found among ethnic groups in the results of the treatment of pediatric ALL. In general, children with a high level of native American ancestry tend to respond less positively to ALL treatments, which may be related to specific genomic variants found in native American groups. Despite the evidence, few data are available on the distribution of the pharmacogenomic variants relevant to the treatment of ALL in traditional Amerindian populations, such the those of the Amazon region. Given this, the present study investigated 27 molecular markers related to the treatment of ALL in Amerindians from Brazilian Amazonia and compared the frequencies with those recorded previously on five continents, that are available in the 1,000 Genomes database. The variation in the genotype frequencies among populations was evaluated using Fisher's exact test. The False Discovery Rate method was used to correct the results of the multiple analyses. Significant differences were found in the frequencies of the majority of markers between the Amerindian populations and those of other regions around the world. These findings highlight the unique genetic profile of the indigenous population of Brazilian Amazonia, which may reflect a distinct therapeutic profile for the treatment of ALL in these populations.